de Maio M. (2018): Myomodulation with Injectable Fillers: An Innovative Approach to Addressing Facial Muscle Movement
M. de Maio · Aesthetic Plastic Surgery, 2018PMID: 29549406
Supports: Introduces the concept of myomodulation — using strategically placed HA fillers to modulate facial muscle movement by addressing structural deficiencies that affect muscle stability and interaction. Provides a biomechanical framework considering synergistic/antagonistic muscle group balance. Demonstrates how filler placement can rebalance abnormal muscle activity and restore youthful facial appearance, underpinning the 8-point non-surgical facelift technique.
Limitations: Level V evidence (expert opinion with case illustrations). No controlled clinical data or quantitative outcome measures. Conceptual framework requiring further clinical validation.
View on PubMed →Cotofana S. et al. (2016): The Anatomy of the Aging Face: A Review
S. Cotofana, A.A.M. Fratila, T.L. Schenck, W. Redka-Swoboda, I. Zilinsky, T. Pavicic · Facial Plastic Surgery, 2016PMID: 27248022
Supports: Comprehensive review of age-related morphological changes across all facial layers: bone, ligaments, muscles, fat, and skin. Establishes that ageing occurs at different onset and speed across structures, individuals, and ethnic groups. Supports rationale for deep structural volumisation at multiple facial points rather than superficial wrinkle filling, underpinning multi-point lift approaches.
Limitations: Narrative review, not a clinical study. No quantitative data on treatment outcomes. Focuses on Caucasian anatomy predominantly; ethnic variation acknowledged but not fully characterised.
View on PubMed →Raspaldo H. (2008): Volumizing Effect of a New Hyaluronic Acid Sub-Dermal Facial Filler: A Retrospective Analysis Based on 102 Cases
H. Raspaldo · Journal of Cosmetic and Laser Therapy, 2008PMID: 18788032
Supports: Retrospective analysis of 102 patients (93 female, 9 male; mean age 51.27) receiving Voluma HA sub-dermal filler in the midface. Investigator Global Aesthetic Improvement assessment showed most patients 'much' or 'very much' improved at 1 month and 6-18 months. Volume loss assessment confirmed most patients maintained stage 1-2 (normal/slight ptosis) at 6-18 months. Patient efficacy rated 'very good' or 'good' in most cases.
Limitations: Retrospective single-centre study. No control group. Combination treatment with botulinum toxin acknowledged but not isolated. Further methodologically rigorous studies needed to establish Voluma performance alone and in combination.
View on PubMed →Sundaram H. et al. (2016): Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A — Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations
H. Sundaram, S. Liew, M. Signorini, A.V. Braz, S. Fagien, A. Swift, K.L. De Boulle, H. Raspaldo, A.R. Trindade de Almeida, G. Monheit · Plastic and Reconstructive Surgery, 2016PMID: 27119917
Supports: Multinational expert consensus (Global Aesthetics Consensus Group) establishing combined HA filler + botulinum toxin as standard of care. Recommends patient-tailored approach considering physiologic/chronologic age, ethnically associated facial morphotypes, and sex/culture-based aesthetic ideals. Lower toxin dosing to modulate (not paralyse) muscles indicated where volume deficits influence muscular activity. Focus on aesthetic units rather than isolated rhytides optimises results. Emerging objective is facial harmonisation rather than rejuvenation.
Limitations: Level V evidence (consensus/expert opinion). Recommendations reflect combined use of specific Hylacross/Vycross HA products. Longitudinal outcome data from combined treatments still limited.
View on PubMed →de Maio M. (2021): MD Codes: A Methodological Approach to Facial Aesthetic Treatment with Injectable Hyaluronic Acid Fillers
M. de Maio · Aesthetic Plastic Surgery, 2021PMID: 32445044
Supports: Introduces MD Codes system — specific anatomical subunits for HA filler injection, each specifying target depth, delivery tool (needle/cannula), technique (aliquot, bolus, fanning), and minimum product volume for visible results. Algorithms focus on reducing unfavourable facial attributes (saggy, tired, sad, angry) and enhancing positive ones (attractive, younger, contoured, feminine/masculine). Provides a universal symbolic language reducing variability in injection technique. Three case studies illustrate application for sagginess, tiredness, and sadness.
Limitations: Level IV evidence. Case-study-based illustration (3 cases only). No controlled comparison with non-systematic approaches. Developed by a single author; independent validation studies needed.
View on PubMed →*PRP London Clinic provides these references for educational purposes. Our Clinical Board regularly reviews emerging peer-reviewed literature to ensure our protocols align with the latest advancements in regenerative medicine.